Clinical and economic analysis of pharmacotherapy of patients with toxic hepatitis in the Kharkiv hospital
DOI:
https://doi.org/10.24959/cphj.15.1343Keywords:
drugs for treating toxic hepatitis, clinical and economic analysis, pharmacotherapyAbstract
The integrated ABC/VEN/frequency analysis was used to conduct the clinical and economic analysis of pharmacotherapy of patients with toxic hepatitis (TH) in the Kharkiv hospital. It has been found that pharmacotherapy in the Gastroenterology department in the Kharkiv hospital did not always comply with the clinical protocol of TH treatment because only 15% of patients received all four essential types of pharmacotherapy recommended by the clinical protocol (detoxication therapy, medicines for normalization of the gastrointestinal tract, hepatotropic drugs and vitamins), and 85% of patients were treated with 1-3 drugs for TH. Most drugs (4-7) were prescribed to patients for treating comorbidities, indicating polypharmacy in pharmacotherapy of patients with the primary diagnosis “toxic hepatitis”. Comparison of the results of the integrated ABC/VEN/frequency analysis indicates that the main funds in the Kharkiv hospital were spent on vitally necessary medicines that were a greater proportion of prescriptions. However, TH pharmacotherapy in this healthcare institution did not always comply with the normative documents since a significant portion of funds from 7.85% to 22.13% was spent on drugs missing in the clinical protocols for treating TH and comorbidities, as well as in the National Drug Formulary of Ukraine (the 5th edition). Therefore, it is possible to optimize the costs by reducing prescriptions of minor drugs and administering those drugs that are included in the clinical protocol of TH treatment.
References
Бакулин И. Г. Возможности применения гепатопротекторов в практике врача-терапевта / И. Г. Бакулин, Ю. Г. Сандлер // Consilium medicum. Гастроэнтерология. – 2010. – № 8. – С. 72–76.
Ипатова О. М. Фосфоглив: механизм действия и применения в клинике / О. М. Ипатова. – М.: изд-во ГУ НИИ биомед. химии РАМН, 2005. – 318 с.
Клініко-економічний аналіз етіотропної противірусної та патогенетично-симптоматичної фармакотерапії стаціонарних хворих на хронічні вірусні гепатити : метод. рек. / Нац. фар-мац. ун-т МОЗ України [та ін.] ; уклад.: Немченко А.С., Федяк І.О. – К., 2011. – 31 с.
Клінічний протокол надання медичної допомоги хворим на хронічні гепатити (Наказ МОЗ України від № 271 від 13.06.2005 р.) [Електронний ресурс]. – Режим доступу до сай-ту: http://www.dec.gov.ua.
Морозов А.М., Яковлєва Л.В., Бездітко Н.В. та ін. Оцінка клінічної та економічної доціль-ності використання лікарських засобів у лікувально-профілактичному закладі (супровід формулярної системи): Метод. рекоменд. – Х.: Стиль-Издат, 2013. – 36 с.
Програмний комплекс «Аптека» компанії «Моріон» [Електронний ресурс]. – Режим до-ступу до сайту: http://pharmbase.com.ua/poisk/.
Teo Y. L. Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review / Y. L. Teo, H. K. Ho, A. Chan // Expert Opin. Drug Metab. Toxicol. – 2004. – № 15. – Р. 1-12.
Topdagi O. The frequency of complications and the etiology of disease in patients with liver cir-rhosis / O. Topdagi, N. Okcu, N. Bilen // Eurasian. J. Med. – 2014.– Vol. 46(2). – Р. 110–114.
Senior J. R. Evolution of the food and drug administration approach to liver safety assessment for new drugs: current status and challenges / J. R. Senior // Drug Saf. – 2014. – Vol. 37, № 11. – Р. 9–17.
Downloads
Published
Issue
Section
License
Copyright (c) 2015 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
